Survodutide
Also known as: BI 456906
A dual GLP-1/glucagon agonist with near 19% weight loss in Phase 3 trials, also targeting MASH liver disease.
Reviewed by Dr. Sarah Mitchell, PharmD, BCPS
Lead Researcher · 12+ years in peptide therapeutics
~6–7 days
4.8–6.0 mg weekly
Subcutaneous injection
Mechanism of Action
Combines GLP-1 appetite suppression with glucagon-mediated thermogenesis and hepatic fat mobilization for dual metabolic benefit.
Key Research Areas
Frequently Asked Questions
What is Survodutide?▾
How does Survodutide work?▾
What is the recommended dosage for Survodutide?▾
What is the half-life of Survodutide?▾
Is Survodutide FDA approved?▾
Ready to get started with Survodutide?
Order from our COA-verified partner — free US shipping, pharmaceutical-grade quality.
Research Disclaimer
The information provided about Survodutide is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare professional before starting any peptide protocol. Products discussed have not been evaluated by the FDA unless explicitly noted.